Ngwọta Nchikota Ọhụrụ maka Mgbagwoju Ọrịa Ọrịa shuga kpatara nke Cornea

RegeneRx Biopharmaceuticals, Inc. na-akọ na ndị nchọpụta egosipụtawo ọgwụgwọ ọgwụgwọ nke Thymosin Beta 4 (Tβ4) dị ka ọgwụgwọ nchikota megide hyperglycemia (ọrịa shuga) na-akpata mgbanwe na mkpụrụ ndụ epithelial corneal mmadụ.

"Ọmụmụ ihe anyị mere ka ọ pụta ìhè na nke mbụ Tβ4 na vasoactive intestinal peptide (VIP) ọgwụgwọ combo na-arụ ọrụ dị mkpa n'ịhazi nkwụsi ike nkwụsịtụ na nhazigharị cytoskeleton [nke cornea], nke nwere njikọ chiri anya na iguzosi ike n'ezi ihe. Ọzọkwa, Tβ4 na-akwadosi ike ọrụ ya dị ka ọgwụgwọ mgbakwunye maka mgbochi corneal ọrịa shuga na-enweghị mmetụta ọ bụla, si otú a na-ebelata ọghọm nke ụzọ nlekọta [anya] ugbu a, "dị ka otu nyocha ahụ siri kwuo.

E gosipụtara nyocha a na Association for Research in Vision and Ophthalmology (ARVO) 2022 nzukọ, emere May 1-4, 2022, na Denver, Colorado. Ndị otu nyocha ahụ gụnyere ndị ọkà mmụta sayensị na ndị dọkịta si Wayne State University School of Medicine na Detroit, MI; Mahadum Central Florida College of Health Prọfesọ na Sayensị na Orlando, FL; na Mahadum Mansoura na Mansoura, Egypt. Ndị ụlọ ọrụ ahụike mba, Eversight Center maka nyocha ọhụụ na ụlọ akụ anya, na nyocha iji gbochie ìsì.